Literature DB >> 20661030

Posthypoxic myoclonus (Lance-Adams syndrome) treated with lacosamide.

Norbert Galldiks, Lars Timmermann, Gereon Rudolf Fink, Lothar Burghaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20661030     DOI： 10.1097/WNF.0b013e3181e1613f

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  7 in total

Review 1.  The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience.

Authors:  Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk
Journal:  Ther Adv Neurol Disord       Date:  2016-11-29       Impact factor: 6.570

Review 2.  Antiseizure Drugs and Movement Disorders.

Authors:  Michel Sáenz-Farret; Marina A J Tijssen; Dawn Eliashiv; Robert S Fisher; Kapil Sethi; Alfonso Fasano
Journal:  CNS Drugs       Date:  2022-07-21       Impact factor: 6.497

Review 3.  Physiology-Based Treatment of Myoclonus.

Authors:  Ashley B Pena; John N Caviness
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Add-on perampanel in Lance-Adams syndrome.

Authors:  Bernhard J Steinhoff; Matthias Bacher; Christoph Kurth; Anke M Staack; Reinhold Kornmeier
Journal:  Epilepsy Behav Case Rep       Date:  2016-06-01

5.  Volatile anesthetic for the control of posthypoxic refractory myoclonic status.

Authors:  Vivek Rayadurg; Radhakrishnan Muthuchellappan; Umamaheshwara Rao
Journal:  Indian J Crit Care Med       Date:  2016-08

Review 6.  Post-hypoxic Myoclonus: Current Concepts, Neurophysiology, and Treatment.

Authors:  Harsh V Gupta; John N Caviness
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-09-17

7.  Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance-Adams Syndrome.

Authors:  Giulietta M Riboldi; Steven J Frucht
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-06-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.